Top Stories
Tempus ECG-PH is the techbio's third tool cleared in the US for cardiology.
Radiology accounted for more than 1000 of the devices reviewed, yet only three were linked to prospective trials, while subgroup testing was rare across the studies researchers found.
The Cancer Research Horizons deal is Bioptimus' third STELA partnership since the project launched in March.
PrecivityAD2 is the first authorised blood test in the US for adults as young as 40 with cognitive symptoms.
Bristol Myers Squibb is the latest pharma giant to tap Chai's AI models, following recent deals with Pfizer, Novartis, Eli Lilly and argenx.
Conference News
Investigator-led abstracts will explore new data on FAI-Score's prognostic value, alongside emerging applications in stroke prediction and virtual biopsy of arterial inflammationOXFORD, England and ST...
Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DCPresentation Title: Assessing Treatment-Associated Brain Network Changes Foll...
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business...
Results characterized by continued strong commercial momentum and improved operating performanceConference call/webcast today at 5:00 pm ETTORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter M...
Real-world evidence on NSCLC treatment patterns and outcomes showcases Flatiron's unified, global oncology engineNEW YORK--(BUSINESS WIRE)-- Flatiron Health today announced its presence at the IASLC 2...
